News

The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. The acquisition aligns with Servier’s strategic goal in rare neurology,

The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Sonefpeglutide combines Hanmi’s proprietary technology and has previously achieved approval from the US Food and Drug

This marks the first approved immunotherapy combination for this patient segment in the US. The approval relies on positive data from the POTOMAC Phase III trial, which was

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four

If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated

Elunetirom is an oral, once daily, brain-penetrant CNS thyroid hormone receptor (CNS-TR) agonist in development for bipolar depression and major depressive disorder (MDD). The therapy is intended as

This move strengthens vaccine supply resilience in Colombia and creates a pathway for SK bioscience’s expansion into Latin America. The Colombian Ministry of Health and Social Protection, National

The therapy uses patients’ immune cells, developed into mature macrophages, which are then re-infused to break down scar tissue and promote the growth of healthy liver cells. In

The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a